XTL Biopharmaceuticals-ADRXTLB
13F holders, Q2 2026 (June 30)3holders −3
1new positions
4sold out
$2.73avg. 13F price*
At the end of Q2 2026, 3 institutions reported holding XTL Biopharmaceuticals-ADR (XTLB) in their 13F filings, down 3 from Q1 2026. 1 opened new positions and 4 sold out. The largest holders were Rhumbline Advisers ($17K), GAMMA Investing LLC ($3K) and UBS Group AG ($341).
- Company
- XTL Biopharmaceuticals-ADR
- CUSIP
- 98386D406
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $341 |
| Exits | 4 | $153K |
All 13F filers, Q1 2026 → Q2 2026: 366 shares bought and 65,502 shares sold, net −65,136 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Rhumbline Advisers | 0.00% | Add +4.0% | 6,228 | $17K |
| GAMMA Investing LLC | 0.00% | Reduce -64.2% | 1,213 | $3K |
| UBS Group AG | 0.00% | New | 125 | $341 |
"% of holder's portfolio" is XTLB's weight in each manager's 13F, not the share of XTL Biopharmaceuticals-ADR the manager owns.